

Idiopathic Pulmonary Fibrosis (IPF)

OVERVIEW

IPF is a fatal condition characterized by scarring and fibrosis of alveolar septae more common in middle-aged men possibly related to collagen vascular disease, with positive rheumatoid serology. It is a clinically aggressive disease with rapid onset of dyspnea, orthopnea, hemoptysis, cyanosis, clubbing of fingers and toes, pulmonary hypertension, bibasilar rales, non-productive cough, leading to death within 3-6 years.

This report utilizes a combination of qualitative and quantitative market research to explore both the current and future dynamics of rapidly evolving treatment paradigms. The qualitative analysis is fueled by interviews with leading US peer-nominated experts in IPF. The quantitative portion leverages our proprietary network of specialists both in office-based practices with a sizeable IPF patient caseload and those based in Interstitial Lung Disease Centers across the US.

SAMPLE AND METHODOLOGY

Market Dynamix: IPF is based on a series of in-depth qualitative interviews with the leading clinical experts in the field (n=15) combined with a quantitative survey of US pulmonologists (n=100) who are part of the Spherix proprietary network of specialists. The survey was conducted in November 2015 and respondents met the following criteria:

- Specialists in pulmonology
- In practice 2 to 30 years
- Balanced sample from across US

KEY QUESTIONS ANSWERED:

- What is the comparative level of unmet need for new products to treat patients with idiopathic pulmonary fibrosis?
- How familiar are pulmonologists with the current PhII & PhIII compounds?
- How are the current treatments, Ofev and Esbriet, differentiated?
- What are the challenges clinicians face when treating IPF?

DELIVERABLES

- PowerPoint deck with key findings
- Frequency tables and summary statistics
- Cross tabulation analysis
- Custom presentation (in-person or webcast)
- Available December 2015

Products Profiled:

Commercial Products*:

Esbriet (Roche)

Ofev (Boehringer Ingelheim)

**Brand names and trademarks of respective organizations*

Pipeline Agents: AF-219 (Afferent), FG-3019 (FibroGen), simtuzumab (Gilead), STX-100 (Biogen), tipelukast (MediciNova)

Related Deliverables 2015:

RealWorld Dynamix—IPF

A robust, HIPAA-certified IPF patient audit of 800 patients in the US recently seen by qualified pulmonologists (n~200 pulmonologists). The patient audit is integrated with physician demographics and attitudes and includes chart data as well as physician commentary on why certain treatment decisions are made as well as the future outlook for each patient

- Patient clinical and social demographics
- Co-morbidities
- Concomitant medications
- Treatment History, Referral Patterns, Co-Management and more

Available: December 2015, \$75,000

Comes with de-identified patient database

Subscription Options:

- Market Dynamix: IPF, \$39,500
- 20% discount on both offerings when purchased as a package

To order or to get more information, please contact info@spherixglobalinsights.com
or call 800-661-0571 (US) or (41) 41 747 18 72 (EU)